SOMAXON PHARMACEUTICALS, INC.: 10-Q filed 2012-05-10
What SOMAXON PHARMACEUTICALS, INC. reported in its quarterly report filed 2012-05-10 (fiscal Q1 2012): 30 published measures, 58 facts as tagged in accession 0001193125-12-223882.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-05-10
- Fiscal period
- fiscal Q1 2012
- Accession
- 0001193125-12-223882 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SOMAXON PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 12,353,000 | USD | |
| At 2011-12-31 | 15,859,000 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 7,141,000 | USD | |
| At 2011-12-31 | 9,318,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 5,212,000 | USD | |
| At 2011-12-31 | 6,541,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 7,754,000 | USD | |
| At 2011-12-31 | 10,668,000 | USD | |
| At 2011-03-31 | 25,360,000 | USD | |
| At 2010-12-31 | 21,008,000 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -2,117,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | -17,038,000 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -2,914,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | -11,248,000 | USD | 90 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-03-31 | 85,000 | USD | 90 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-03-31 | 1,000 | USD | 90 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-03-31 | 15,599,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | -278,249,000 | USD | |
| At 2011-12-31 | -276,132,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 574,000 | USD | |
| At 2011-12-31 | 634,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 688,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 1,195,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -2,133,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | -17,053,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 10,539,000 | USD | |
| At 2011-12-31 | 13,935,000 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 6,616,000 | USD | |
| At 2011-12-31 | 8,828,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 675,000 | USD | |
| At 2011-12-31 | 1,774,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 1,525,000 | USD | |
| At 2011-12-31 | 1,950,000 | USD |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 187,000 | USD | |
| At 2011-12-31 | 264,000 | USD |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 4,600,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 18,593,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-01-01 to 2011-03-31 | 419,000 | USD | 90 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 48,108,000 | shares | |
| At 2011-12-31 | 48,063,000 | shares |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 1,039,000 | USD | |
| At 2011-12-31 | 1,089,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 525,000 | USD | |
| At 2011-12-31 | 490,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 5,941,000 | USD | |
| At 2011-12-31 | 7,054,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -2,117,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | -17,034,000 | USD | 90 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 60,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 52,000 | USD | 90 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 50,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 30,000 | USD | 90 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -425,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | -4,703,000 | USD | 90 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -77,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 497,000 | USD | 90 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -1,099,000 | USD | 91 |
| 2011-01-01 to 2011-03-31 | 1,257,000 | USD | 90 |
Inspect the source
- Entity
- SOMAXON PHARMACEUTICALS, INC. / CIK 0001339455
- Captured
- SEC response SHA-256
3a08923985d0edd29104bdcd4e0f5285336da2293200189c0990df3c7992d1cf
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001339455.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))